HistoIndex Revolutionizes MASH Diagnosis with AI Technology

Published on 8.11.25

HistoIndex is developing AI-based digital pathology solutions to improve the assessment of treatment response and disease severity in Metabolic Dysfunction-associated Steatohepatitis (MASH). Founded in 2010, the company uses cutting-edge biophotonic technology with AI analysis to visualize and quantify fibrosis in biological tissues. Their breakthrough tools are currently used to accelerate clinical research, expedite pharmaceutical drug development, and transform medical standards, as seen in their Fibrosight and Qfibrosis solutions (histoindex.com).

References

https://www.prnewswire.com/news-releases/histoindex-marks-another-step-forward-with-fibrosight-plus-introducing-ai-based-quantitative-analysis-in-fibrosis-assessment-302521784.html

Back

See Newsfeed: Artificial Intelligence